Latest news with #Clarity
The Irish Sun
24-06-2025
- Business
- The Irish Sun
RTE star tipped to replace Joe Duffy as Liveline host as ‘it looks like decision made' after presenter's TV show axed
LIVELINE favourite Katie Hannon is tipped to take over from Joe Duffy after announcing the shock end of her TV show today. RTE chiefs confirmed that its flagship Monday night current affairs series, Upfront with Katie Hannon, Advertisement 1 Joe Duffy's most likely successor has been revealed Credit: Copyright remains with handout provider And as Hannon — currently the 1/5 odds-on fave with She will also host a new TV series ahead of the Presidential election, which must take place by November. In a statement, Hannon, 53, said: 'I'm very proud of what we achieved on Upfront. Advertisement read more on joe duffy "We managed to buck the international trend and actually grew our audience on linear television and our digital footprint. "It was a privilege to work with our small team of talented and hardworking colleagues led by our editor Janet Traynor. 'I also want to thank all of those who came into our studio and trusted us with their stories and contributed to the national conversation on the issues that matter to all of us. "I'm disappointed that we won't be able to keep that conversation going.' Advertisement Most read in News TV A spokeswoman for RTE said: 'The decision to wrap production has been made due to the prioritising of people and financial resources, as the organisation incurs significant change and becomes smaller. 'As part of the organisation's new direction strategy in the prioritising of digital content, it has recently launched a news podcast and 'Clarity', a new strand beginning to tackle increasing misinformation and disinformation challenges.' Joe Duffy fights back tears on air Other employees from the show will continue working with RTE News and Current Affairs section of the national broadcaster. Upfront started in January 2023 as a replacement to Advertisement The most recent series of Upfront With Katie Hannon, which ran from September 24 to May 25, had an average audience rating of 198,000. TOP TV This represents a 25.8 per cent of audience share, with these figures being up from an average of 168,000 and 23.7 per cent in series two. Similarly, the series grew on the RTE Player, attracting 269,000 streams in series three, from 209,000 in series two. Clips from the programme have also generated over 3.3 million video views on Advertisement A source told us: 'Katie Hannon is the obvious successor to Joe on Liveline. She has been filling in for so long.' Katie currently leads the way as the bookmakers' favourite to replace the 69-year-old. Alex Apati of Ladbrokes said: "It looks as though a decision has been made when it comes to Joe Duffy's replacement. With Upfront now cancelled, Katie Hannon's diary is now clear for the iconic gig, and the odds suggest it's hers." Advertisement
Sunday World
24-06-2025
- Entertainment
- Sunday World
RTÉ fuel rumours of Joe Duffy replacement after cancelling Upfront with Katie Hannon
The show which was broadcast on Monday nights at 10.35pm started in January 2023 as a replacement to the Claire Byrne Live show. This Friday will be Joe Duffy's final time on the airwaves. Katie Hannon's Monday night RTÉ show will not return in September, paving the way for her to possibly take over the Liveline gig. This Friday will be Joe Duffy's final time on the airwaves, after 27 years fronting the daily radio show and 37 years working with RTÉ. Speculation had put Hannon as one of the front-runners for the coveted gig, given that she has filled in for Duffy so much in recent times. RTÉ confirmed to the Sunday World that her current affairs show Upfront with Katie Hannon has come to an end and will not be returning in September after three seasons on-air. The statement added that Hannon will continue as one of the anchors of the popular Behind the Story podcast, which will launch daily later this year. This Friday will be Joe Duffy's final time on the airwaves. She will also present a new TV series in the lead-up to the presidential election in October. Katie Hannon said: "I'm very proud of what we achieved on Upfront. We managed to buck the international trend and actually grew our audience on linear television and our digital footprint. It was a privilege to work with our small team of talented and hardworking colleagues led by our editor Janet Traynor. "I also want to thank all of those who came into our studio and trusted us with their stories and contributed to the national conversation on the issues that matter to all of us. I'm disappointed that we won't be able to keep that conversation going." A spokeswoman for RTÉ said: 'The decision to wrap production has been made due to the prioritising of people and financial resources, as the organisation incurs significant change and becomes smaller. RTÉ broadcaster Katie Hannon. Photo: Gerry Mooney News in 90 Seconds - June 24th 'As part of the organisation's new direction strategy in the prioritising of digital content, it has recently launched a news podcast and 'Clarity', a new strand beginning to tackle increasing misinformation and disinformation challenges.' The show which was broadcast on Monday nights at 10.35pm started in January 2023 as a replacement to the Claire Byrne Live show. RTÉ News & Current Affairs presenter Katie Hannon will continue as one of the anchors of the popular Behind the Story Podcast, which is planned to launch daily later this year, and she will also present a new TV series in the lead up to the presidential election in October. Other employees will continue working with RTÉ News & Current Affairs - there are a number of internal vacancies and options for redeployment within the division. The programme which was broadcast on Monday nights at 10.35pm began in January 2023 and featured a weekly panel of four guests and an audience of up to 40 contributors. In its most recent series (Sept 24 - May 25), Upfront with Katie Hannon was watched by an average of 198,000 viewers, a 25.8pc audience share, up from an average of 168,000 and 23.7pc in series two (Sept 23 - May 24). Similarly, the series grew on the RTE Player attracting 269,000 streams in series three, from 209,000 in series two (Sept 23 - May 24). Clips from the programme have also generated over 3.3 million video views on Instagram. Across RTÉ's television services, News & Current Affairs coverage currently includes the One O'Clock News, Six One News, Nine O'Clock News, Prime Time, RTÉ Investigates, The Week in Politics, Nuacht, News with ISL, news2day, Nationwide, Leaders Questions, Fóram, European Parliament Report, Political Party Conferences, RTÉ News specials, Budget coverage, Election coverage and National Commemoration Events coverage. Details of all new programming will be announced as part of RTÉ's New Season launch in August.
Irish Independent
24-06-2025
- Entertainment
- Irish Independent
RTÉ cancels flagship current affairs show Upfront with Katie Hannon
This Friday will be Joe Duffy's final time on the airwaves, after 27 years fronting the daily radio show and 37 years working with RTÉ. Speculation had put Hannon as one of the front-runners for the coveted gig, given that she has filled in for Duffy so much in recent times. RTÉ confirmed to the Irish Independent that her current affairs show Upfront with Katie Hannon has come to an end and will not be returning in September after three seasons on-air. The statement added that Hannon will continue as one of the anchors of the popular Behind the Story podcast, which will launch daily later this year. She will also present a new TV series in the lead-up to the presidential election in October. Katie Hannon said: "I'm very proud of what we achieved on Upfront. We managed to buck the international trend and actually grew our audience on linear television and our digital footprint. It was a privilege to work with our small team of talented and hardworking colleagues led by our editor Janet Traynor. "I also want to thank all of those who came into our studio and trusted us with their stories and contributed to the national conversation on the issues that matter to all of us. I'm disappointed that we won't be able to keep that conversation going." A spokeswoman for RTÉ said: 'The decision to wrap production has been made due to the prioritising of people and financial resources, as the organisation incurs significant change and becomes smaller. 'As part of the organisation's new direction strategy in the prioritising of digital content, it has recently launched a news podcast and 'Clarity', a new strand beginning to tackle increasing misinformation and disinformation challenges.' The show which was broadcast on Monday nights at 10.35pm started in January 2023 as a replacement to the Claire Byrne Live show. ADVERTISEMENT RTÉ News & Current Affairs presenter Katie Hannon will continue as one of the anchors of the popular Behind the Story Podcast, which is planned to launch daily later this year, and she will also present a new TV series in the lead up to the presidential election in October. Other employees will continue working with RTÉ News & Current Affairs - there are a number of internal vacancies and options for redeployment within the division. The programme which was broadcast on Monday nights at 10.35pm began in January 2023 and featured a weekly panel of four guests and an audience of up to 40 contributors. In its most recent series (Sept 24 - May 25), Upfront with Katie Hannon was watched by an average of 198,000 viewers, a 25.8pc audience share, up from an average of 168,000 and 23.7pc in series two (Sept 23 - May 24). Similarly, the series grew on the RTE Player attracting 269,000 streams in series three, from 209,000 in series two (Sept 23 - May 24). Clips from the programme have also generated over 3.3 million video views on Instagram. Across RTÉ's television services, News & Current Affairs coverage currently includes the One O'Clock News, Six One News, Nine O'Clock News, Prime Time, RTÉ Investigates, The Week in Politics, Nuacht, News with ISL, news2day, Nationwide, Leaders Questions, Fóram, European Parliament Report, Political Party Conferences, RTÉ News specials, Budget coverage, Election coverage and National Commemoration Events coverage.
Yahoo
13-06-2025
- Health
- Yahoo
DISCO topline results: 64Cu-SARTATE is highly effective in detecting tumours in NET patients compared to SOC imaging. Phase III planning underway.
HIGHLIGHTS Topline data from Clarity's diagnostic Phase II trial, DISCO, confirms that 64Cu-SARTATE is safe and highly effective compared to standard-of-care (SOC) imaging at detecting lesions in patients with neuroendocrine tumours (NETs). DISCO compared the diagnostic performance of 64Cu-SARTATE at an average of 4 hours (between 3 to 5 hours) and 20 hours post-administration (same-day and next-day imaging, respectively) to 68Ga-DOTATATE. 64Cu-SARTATE lesion detection substantially outperformed that of 68Ga-DOTATATE. 64Cu-SARTATE detected 393 to 488 lesions, and 68Ga-DOTATATE identified 186 to 265 lesions among 45 study participants across the readers. Out of all the lesions identified by the readers, 230-251 were deemed to be discordant (i.e. only present on one of the scans, 68Ga-DOTATATE or 64Cu-SARTATE positron emission tomography [PET] / computed tomography [CT]). Of these lesions, 93.5% (average across readers) were only detected on the 64Cu-SARTATE PET/CT scans. The number of discordant lesions detected by 64Cu-SARTATE on the same-day and next-day scans was comparable. Approximately half of all the discordant lesions had an available standard-of-truth (SOT), such as histopathology or conventional imaging. The identified discordant lesions yielded a lesion-level sensitivity of 93.4% to 95.6% (95% confidence interval [CI]: 65.1, 99.5) for 64Cu-SARTATE (across both timepoints) and only 4.4% to 6.6% (95%CI: 0.5, 34.9) for 68Ga-DOTATATE across both readers. 64Cu-SARTATE was deemed safe and well tolerated. Only 7 (15.6%) participants experienced 64Cu-SARTATE-related adverse events (AEs). No serious treatment-emergent AEs were observed in the study. Based on the exciting preliminary results of the DISCO trial, Clarity will commence next steps to conduct a registrational Phase III study of 64Cu-SARTATE in NETs with the US Food and Drug Administration's (FDA) guidance. SYDNEY, June 5, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce positive results from the diagnostic Phase II DISCO trial (NCT04438304)[1] with 64Cu-SARTATE in patients with known or suspected NETs. DISCO trial design DISCO is a "Diagnostic Imaging Study of 64COpper-SARTATE Using PET on Patients with Known or Suspected Neuroendocrine Tumours". It assessed the performance of Clarity's SARTATE imaging product as a potential new method to diagnose and manage NETs. The trial aimed to build on earlier clinical experience with 64Cu-SARTATE in patients with NETs, which demonstrated that the diagnostic has excellent imaging characteristics and suggested that 64Cu-SARTATE PET/CT provides comparable or superior lesion detection to 68Ga-DOTATATE PET/CT in all patients, especially in the liver[2]. DISCO recruited participants with Gastroenteropancreatic NETs (GEP-NETs) across 4 sites in Australia, comparing the diagnostic performance of 64Cu-SARTATE PET at an average of 4 hours (between 3 and 5 hours) and approximately 20 hours post-administration (same-day and next-day imaging, respectively) to the current SOC, 68Ga-DOTATATE PET. Participants were required to have undergone a pre-study 68Ga-DOTATATE PET/CT scan within 5 weeks, but not closer than 6 hours prior to the administration of 64Cu-SARTATE as part of their routine clinical care. The trial was initially designed to enrol up to 63 patients, based on the anticipated lesion-level discordance rate between 64Cu-SARTATE and 68Ga-DOTATATE PET. Following a pre-planned early analysis of the data collected during the study, the sample size was adjusted to 45 patients, allowing for an earlier enrolment completion. Study participants were dosed with 200 MBq of 64Cu-SARTATE. Both the 64Cu-SARTATE and 68Ga-DOTATATE PET/CT scans were reviewed by 2 blinded central readers. Participants were followed for up to 12 months to complete additional investigations (e.g. biopsy and conventional imaging) and obtain the SOT used to verify discordant findings between the scan pairs. The verification of discordant findings against the SOT evidence (as true- or false-positive findings) was completed by an independent central assessor, distinct from the central readers evaluating the 64Cu-SARTATE and 68Ga-DOTATATE scans. Lesion-level sensitivity was calculated for the discordant lesions between the scan pairs, with each true-positive discordant lesion on one scan considered a false-negative lesion on the other scan, and each false-positive discordant lesion on one scan considered a true-negative lesion on the other scan. Topline results The results indicate that lesion detection by 64Cu-SARTATE (regardless of imaging timepoint) substantially outperformed that of 68Ga-DOTATATE. 64Cu-SARTATE detected 393 to 488 lesions, and 68Ga-DOTATATE identified 186 to 265 lesions among 45 participants across the readers (Figure 1). Out of all lesions identified by the readers, 230-251 were deemed to be discordant between 64Cu-SARTATE and 68Ga-DOTATATE PET/CT, with 93.5% (average across readers and imaging days) of these discordant lesions detected on the 64Cu-SARTATE scans only. A previously completed Phase I study demonstrated a 1.7 fold increase (median of 6.70 vs. 3.92, p=0.002) in contrast (i.e. lesion-to-background ratio) for 64Cu-SARTATE PET/CT performed at 4 hours post-administration compared to 68Ga-DOTATATE PET/CT2. This improvement in contrast may explain the detection of additional lesions observed in the DISCO trial. The average SUVmax, representing the highest concentration of 64Cu-SARTATE uptake in lesions, was notably high, ranging from 37.42 to 43.90 across both imaging days in the DISCO trial. Approximately half of all discordant lesions had an available SOT, which yielded a lesion-level sensitivity of 93.4% to 95.6% (95%CI: 65.1, 99.5) for 64Cu-SARTATE, including both timepoints, and only 4.4% to 6.6% (95%CI: 0.5, 34.9) for 68Ga-DOTATATE. 64Cu-SARTATE was deemed safe and well tolerated. Only 7 (15.6%) trial participants experienced 64Cu-SARTATE-related AEs, the majority of which were mild (Grade 1) gastrointestinal events, commonly observed in NET patients, and typically resolved within 2 days of onset. No serious treatment-emergent AEs were observed in the study. Based on the findings of the DISCO trial to date, Clarity will commence the next steps to conduct a registrational Phase III study of 64Cu-SARTATE in NETs with the US FDA's guidance. Clarity's Executive Chairperson, Dr Alan Taylor, commented, "We are very excited about the initial topline data from the DISCO trial as 64Cu-SARTATE was confirmed to be safe and very effective in detecting NET lesions in patients with known or suspected disease. The DISCO trial demonstrates a significant advantage of our diagnostic over 68Ga-DOTATATE. 64Cu-SARTATE detected almost double the number of lesions compared to the SOC, and, where SOT was available, a very high lesion-level sensitivity of 93.4% - 95.6% in comparison to just 4.4% - 6.6% for 68Ga-DOTATATE for these discordant findings. In addition to identifying more lesions with our product, lesions detected by 64Cu-SARTATE also exhibited high uptake with low background on the PET scans, making it easier to identify those lesions by readers. Excellent lesion visualisation was also supported by substantial clearance from the liver. The favourable biodistribution of 64Cu-SARTATE PET enabled high-contrast diagnostic imaging for up to approximately 24 hours post-injection (Figure 1), offering greater flexibility in the scheduling of PET/CT scans. "In the DISCO trial, we continue to observe the substantial limitations of the current-generation of short half-life isotope products, what we call isotope-centric medicine. This is clearly illustrated by 68Ga-DOTATATE with imaging timepoints solely dictated by the very short isotope half-life (approximately 1 hour for gallium-68) as opposed to good science and medicine. In contrast, 64Cu-SARTATE highlights the extraordinary benefits of next-generation patient-centric medicine, where imaging is guided by the optimal timepoint to scan and detect lesions, focusing on the needs of the patients and their treating professionals. "We believe that the flexibility of imaging with 64Cu-SARTATE, in comparison to approximately 1 hour with 68Ga-DOTATATE, plays an important role in the detection benefits seen in the DISCO study. We have known this for many years and have demonstrated these advantages of optimal timepoint imaging with different products in our Targeted Copper Theranostic (TCT) platform, including SARTATE. We have seen first-hand in a number of clinical trials that once radiopharmaceutical products are administered, they take time to find the lesion whilst also needing to clear from non-target organs, providing greater contrast. This is known as signal-to-noise ratio or, in our case, tumour-to-background ratio. Having greater contrast is especially important to identify smaller or more difficult to find cancers. "The longer half-life of copper-64, combined with Clarity's proprietary SAR Technology, sets up a strong foundation for next-generation diagnostics, which could be unmatched in the radiopharmaceutical sector. In addition to clinical benefits, the opportunity for high-volume centralised manufacturing and broad, on-demand distribution of ready-to-use diagnostics translates into flexibility and reliability for patients and their treating staff, meaning that every patient with access to PET imaging, including those in underserved and broad geographic areas, may access improved cancer diagnostics. "Patients with NETs are often misdiagnosed and experience delays in receiving the correct diagnosis, which may lead to disease progression and identification of their cancer at later stages. Visualising NET lesions earlier and more accurately may have a significant impact on patient outcomes as it equips clinicians with crucial information on disease burden, helping to determine an optimal treatment plan. As such, the SSTR2 imaging market is an important focus for Clarity. We estimate the NET diagnostic market in the US alone to be around 100,000 scans per year, growing to approximately 120,000 scans per year by 2029. "Importantly, the positive results of the DISCO trial open broader opportunities for the development of 64Cu-SARTATE in additional SSTR2-expressing malignancies beyond NETs, such as certain types of breast and lung cancers, where unmet clinical needs remain high. We believe the SSTR2 market is set to grow substantially with a number of therapies in development for this target, which include large indications such as breast and lung cancers. Subject to the successful completion of these studies, we believe that the imaging market for 64Cu-SARTATE could be as large, if not larger, than the very lucrative prostate cancer imaging market where radiopharmaceuticals currently dominate the diagnostic paradigm. "We look forward to sharing additional data readouts from the trial and presenting the results at future international medical conferences. We plan to rapidly progress discussions with the FDA to initiate a diagnostic registrational Phase III study, as a first key step in expanding SARTATE into the theranostic field of NETs, as well as other SSTR2-expressing cancers, with the copper-64/copper-67 pair. If the findings from the DISCO trial are substantiated in a registrational Phase III study and lead to regulatory approval by the US FDA, 64Cu-SARTATE may play an important role in improving diagnostic accuracy, lesion detection and staging of patients with NETs. These factors could improve clinical decision-making and treatment outcomes, potentially positioning 64Cu-SARTATE as a best-in-class agent for the diagnosis of NETs." About SARTATE SARTATE is a next generation, highly targeted theranostic radiopharmaceutical. It is being developed for diagnosing, staging and subsequently treating cancers that express SSTR2, such as NETs. Like all Clarity products, the SARTATE product can be used with copper-64 (64Cu) for imaging (64Cu-SARTATE) or copper-67 (67Cu) for therapy (67Cu-SARTATE). Disclaimer 64Cu-SARTATE is an unregistered product. The safety and efficacy of 64Cu-SARTATE has not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that this product will become commercially available. About NETs NETs, also known as well-differentiated neuroendocrine neoplasms or carcinoids, represent a heterogeneous group of malignant transformations of cells of the diffuse neuroendocrine system[3]. They most commonly occur in the gastrointestinal tract (48%), lung (25%), and pancreas (9%), but may also originate in other areas, including the breast, prostate, thymus and skin[4]. NETs can either be benign or malignant, as well as non-functional and functional[5]. NETs traditionally have been considered uncommon; however, the incidence has been increasing as a worldwide phenomenon[6]. Overall, it is estimated that more than 20,000 people in the United States are diagnosed with a NET each year[7], and approximately 190,000 people are living with this diagnosis[8]. Patients with NETs present with subtle clinical symptoms, which can lead to a delay in diagnosis of more than 4 years[9]. As such, about 30-75% of NET patients have distant metastases at the time of diagnosis[10]. A 10-year relative survival rate for patients with metastatic GEP-NETs is 3–36%[11]. About Clarity Pharmaceuticals Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers. For more information, please contact: Clarity Pharmaceuticals Dr Alan Taylor Lisa SadetskayaExecutive Chairperson Director, Corporate Communicationsataylor@ lisa@ References [1] Identifier: NCT04438304 [2] Hicks R et al. First-in-human trial of 64Cu-SARTATE PET imaging of patients with neuroendocrine tumours demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. The Journal of Nuclear Medicine. 2019. [3] Cheung VTF, Khan MS. A guide to midgut neuroendocrine tumours (NETs) and carcinoid syndrome. Frontline gastroenterology. 2015;6(4):264-269. [4] Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589-597. [5] Yau H, Kinaan M, Quinn SL, Moraitis AG. Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives. Biologics : targets & therapy. 2017;11:115-122. [6] Leoncini E, Boffetta P, Shafir M, Aleksovska K, Boccia S, Rindi G. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine. 2017 Nov;58(2):368-379. doi: 10.1007/s12020-017 1273-x. Epub 2017 Mar 16. PMID: 28303513; PMCID: PMC5671554. [7] Wu C, Song Z, Balachandra S, Dream S, Chen H, Rose JB, Bhatia S, Gillis A. Charting the Course: Insights into Neuroendocrine Tumor Dynamics in the United States. Ann Surg. 2025 Jun 1;281(6):968-975. doi: 10.1097/SLA.0000000000006331. Epub 2024 May 6. PMID: 38708616; PMCID: PMC11538379. [8] Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589. PMID: 28448665; PMCID: PMC5824320. [9] Basuroy R, Bouvier C, Ramage JK, Sissons M, Srirajaskanthan R. Delays and routes to diagnosis of neuroendocrine tumours. BMC Cancer. 2018 Nov 16;18(1):1122. doi: 10.1186/s12885-018-5057-3. PMID: 30445941; PMCID: PMC6240263. [10] Aluri V. and Dillion, J.S. 2017, "Biochemical Testing in Neuroendocrine Tumors", Endocrinology & Metabolism Clinics of North America, [11] Polee, I.N. et al. 2022, "Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study", European Journal of Cancer, Volume 172, 2022, Pages 252-263, ISSN 0959-8049, • Krasnovskaya et al. Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals. Int J Mol Sci. 2023 May 23;24(11):9154. doi: 10.3390/ijms24119154. This announcement has been authorised for release by the Executive Chairperson. View original content to download multimedia: SOURCE Clarity Pharmaceuticals
Travel Daily News
10-06-2025
- Business
- Travel Daily News
Clarity sees record use of ClarityGo booking platform
Clarity's ClarityGo platform reaches 95% adoption, processes 1m.+ bookings, reduces offline contacts by 23%, and earns high satisfaction for usability and accessibility. Travel management company, Clarity, has announced that its proprietary agent and customer-facing online booking platform, ClarityGo, has seen record adoption levels and customer satisfaction scores since launching to market officially in June 2024. All Clarity customers have now migrated to ClarityGo from the TMC's incumbent third-party online booking tool, and former Agiito customers are expected to complete migration by the end of this year (as part of the integration of the two businesses since Clarity acquired Agiito in 2023). ClarityGo has achieved an exceptional 95% customer adoption rate, demonstrating strong user engagement and satisfaction. Since its launch, the platform has facilitated over a million bookings, with users conducting an impressive 2 million product searches per month. With an average of 45,000 sessions daily and 9.3 bookings per minute, ClarityGo continues to streamline the online travel management experience. The success of its usability and online adoption has led to a remarkable 23% reduction in contacts to Clarity's offline teams over the past year, highlighting its effectiveness in delivering seamless, self-service solutions. Clarity spent three years designing and building the platform, combining in-house expertise with critical customer research to deliver ClarityGo's fast, consumer-grade user experience and omni-channel booking solution enabling customers and agents to seamlessly book flights, hotel, rail and car hire. Customers can start bookings online, which are seamlessly picked up by Clarity's agents to finish offline, if required. The platform is extremely agile, with a consumer-style UI to easily navigate travel options and itineraries in a clear visual format. Unified and relevant search results are returned rapidly and bookable within seconds. ClarityGo has impressive content capabilities including full NDC, GDS and low-cost flights/airfares; academic and marine fares; a database of 1M+ hotels, including Clarity's exclusive Room programme rates; and real-time UK, Eurostar and international rail inventory. The platform is seamlessly integrated with the ClarityGo Mobile App, synching bookings, itineraries, e-wallet and approvals. ClarityGo is also the first and currently only OBT in the industry to achieve externally-audited WCAG 2.2 Level AA accessibility standards accreditation by the Digital Accessibility Centre. It has been designed with inclusivity as standard taking into account sensory differences in vision, sound and touch, and content is accessible via assistive software and screen readers. Customer feedback has been extremely positive including comments such as: 'The migration to ClarityGo has been seamless. The team have been extremely helpful and made the process very easy. I've already received good feedback about the new system and how easy it is to use,' charity sector client. 'Thank you to everyone on the team for their assistance throughout the migration process. We couldn't have hoped for a smoother transition to a new system. Very impressed and great feedback from all users so far!' education sector client Sue Chapman, Executive Director – Product and Commercial, Clarity commented: 'This marks a significant milestone in our technology journey, showcasing the power of both innovation and collaboration. We are proud to lead the way in delivering solutions that truly make a difference for our customers. Our teams have worked tirelessly to bring innovation to life, and seeing it add real value to those using the technology is extremely rewarding. We look forward to continuing to push boundaries, challenge expectations, and create meaningful impact.'
